To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

454

Participants

Timeline

Start Date

September 22, 2023

Primary Completion Date

December 11, 2024

Study Completion Date

December 11, 2024

Conditions
PsoriasisSkin Diseases
Interventions
DRUG

AK111

AK111 regimen 1-subcutaneous injection,until week 24.

DRUG

AK111

AK111 regimen 2-subcutaneous injection,until week 24.

Trial Locations (11)

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

The First Affiliated Hospital of Wannan Medical College, Wuhu

Affiliated Hospital of Chengde Medical University, Chengde

Nanyang First People's hospital national third class a hospital, Nanyang

Yichang central People's hospital, Yichang

The Third Xiangya Hospital of Central South University, Changsha

The affiliated hospital of Xuzhou Medical University, Xuzhou

Dermatology hospital of Jiangxi province, Nanchang

Tianjin academy of traditional Chinese medicine affiliated hospital, Tianjin

Hangzhou First People's hospital, Hangzhou

The first hospital of Jiaxing, Jiaxing

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Akeso

INDUSTRY